HLB bioStep Co.,Ltd. (KOSDAQ:278650)

South Korea · Delayed Price · Currency is KRW

3,865.00

-235.00 (-5.73%)

At close: Nov 13, 2026

Market Cap	66.50B -45.9%
Revenue (ttm)	72.15B +9.3%
Net Income	-18.43B
EPS	-1,114.34
Shares Out	17.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	416,965
Open	4,130.00
Previous Close	4,100.00
Day's Range	3,855.00 - 4,300.00
52-Week Range	1,500.00 - 8,860.00
Beta	-0.35
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About HLB bioStep

HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug development consulting and clinical trial services, and bioanalysis items. The company was formerly known as KNOTUS Co.,Ltd. HLB bioStep Co.,Ltd. was found... [Read more]

Industry Commercial Physical and Biological Research

Founded 2012

Employees 141

Stock Exchange KOSDAQ

Ticker Symbol 278650

Full Company Profile

Financial Performance

In 2025, HLB bioStep's revenue was 74.05 billion, an increase of 27.30% compared to the previous year's 58.17 billion. Losses were -18.96 billion, 121.4% more than in 2024.

Financial Statements